Advertisement
U.S. markets open in 4 hours
  • S&P Futures

    5,302.50
    -5.75 (-0.11%)
     
  • Dow Futures

    40,139.00
    -5.00 (-0.01%)
     
  • Nasdaq Futures

    18,469.00
    -34.75 (-0.19%)
     
  • Russell 2000 Futures

    2,133.10
    -5.30 (-0.25%)
     
  • Crude Oil

    81.61
    +0.26 (+0.32%)
     
  • Gold

    2,215.80
    +3.10 (+0.14%)
     
  • Silver

    24.54
    -0.21 (-0.86%)
     
  • EUR/USD

    1.0783
    -0.0047 (-0.43%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.97
    +0.19 (+1.49%)
     
  • GBP/USD

    1.2592
    -0.0046 (-0.37%)
     
  • USD/JPY

    151.4350
    +0.1890 (+0.12%)
     
  • Bitcoin USD

    70,692.82
    +878.81 (+1.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,961.13
    +29.15 (+0.37%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

A Holistic Look At Genmab A/S (CPH:GEN)

As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Genmab A/S (CPH:GEN), it is a company with robust financial health as well as a excellent future outlook. Below is a brief commentary on these key aspects. For those interested in digger a bit deeper into my commentary, take a look at the report on Genmab here.

Exceptional growth potential with flawless balance sheet

Investors in search of impressive top-line expansion should look no further than GEN, with its expected 71.33% revenue growth in the upcoming year. This is expected to flow down into an impressive return on equity of 26.18% over the next couple of years. GEN’s ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This implies that GEN manages its cash and cost levels well, which is an important determinant of the company’s health. GEN currently has no debt on its balance sheet. This implies that the company is running its operations purely on off equity funding. which is rather impressive for a ø59.00b market cap company. Therefore the company has plenty of headroom to grow, and the ability to raise debt should it need to in the future.

CPSE:GEN Future Profit June 25th 18
CPSE:GEN Future Profit June 25th 18

Next Steps:

For Genmab, there are three pertinent aspects you should further examine:

  1. Historical Performance: What has GEN’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

  2. Valuation: What is GEN worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether GEN is currently mispriced by the market.

  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of GEN? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.

Advertisement